Merck”s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC

Saturday, 3 June 2023, 15:00:00
Based on a subgroup analysis, improvement in event-free survival (EFS) with the KEYTRUDA-based regimen was consistent across all PD-L1 expression subgroups, histology and stage Exploratory subgroup analysis showed a reduction in EFS events with the KEYTRUDA perioperative regimen for patients with or without pathological complete response (pCR) compared with the chemotherapy-placebo regimen KEYNOTE-671 is the eighth positive pivotal study evaluating a KEYTRUDA-based regimen in earlier stages of cancer and the seventh positive pivotal study in lung cancer Merck (NYSE: MRK ), known as MSD outside of the United States and Canada, today announced positive results from the pivotal Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA, Merck”s anti-PD-1 therapy, as a perioperative treatment regimen, which includes treatment before surgery (neoadjuvant) and after surgery (adjuvant), for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer (NSCLC). After a median follow-up of 25.2 months, neoadjuvant KEYTRUDA plus chemotherapy followed by resection and adjuvant single-agent KEYTRUDA significantly improved EFS, reducing the risk of disease recurrence, progression or death by 42% (HR=0.58 [95% CI, 0.46-0.72]; p<0.00001) for patients with resectable stage II, IIIA or IIIB NSCLC versus neoadjuvant placebo plus chemotherapy followed by adjuvant placebo.
— Benzinga

Merck’s KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC

Saturday, 3 June 2023, 15:00:00
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the pivotal Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen, which includes treatment before surgery (neoadjuvant) and after surgery (adjuvant), for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer
— Wallstreet:Online

KEYTRUDA (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma

Saturday, 3 June 2023, 14:00:00
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy as first-line treatment for patients with unresectable advanced pleural mesothelioma. At the final analysis of the study, KEYTRUDA plus chemotherapy
— Wallstreet:Online

3 Undervalued Dow Stocks to Buy Before Wall Street Does

Friday, 2 June 2023, 12:00:43
Wall Street has fallen back in love with rapidly growing tech companies with huge cash hoards and/or tremendous leverage to the artificial intelligence (AI) trend. Meanwhile, it’s turning a cold shoulder to the blue-chip Dow Jones Industrial Average . In fact, the index is down slightly on the year compared with a 25% gain for the Nasdaq . While some of the 30 components should be avoided, there are a handful of undervalued Dow Jones stocks investors should scoop up before they once again catch Wall Street’s attention. The best undervalued Dow stocks are supported by strong trends that are likely to continue for many years. Furthermore, the investor pessimism related to fears about the economy and interest rates that has contributed to the Dow’s underperformance appears to be overdone. There are signs the Federal Reserve may pause its interest rate hike campaign this month, and central bankers are forecasting U.S. gross domestic product (GDP) will increase by an annualized rate of 2% , excluding inflation, this quarter.
— InvestorPlace

APOL1 Mediated Kidney Disease Market is Estimated to be Worth US$ 5753.9 Million and Grow at CAGR of 4.3% by Forecast Period 2033 | Future Market Insights, Inc.

Thursday, 1 June 2023, 15:44:00
NEWARK, DE / ACCESSWIRE / June 1, 2023 / The global APOL1 Mediated Kidney Disease Market is anticipated to attain a valuation of US$ 3779.9 million in 2023 and is expected to reach US$ 5753.9 million by 2033, trailing a CAGR of 4.3% during the projected forecast period. The approval of new drugs in the chronic kidney disease market has multiple benefits. It provides healthcare providers and patients with more treatment options, leading to revenue growth for pharmaceutical companies. It also improves patient access to treatment and encourages ongoing research and development in the field. Furthermore, the high regulatory standards set for new treatments ensure their safety and effectiveness. These factors contribute to the expected growth of the Chronic Kidney Disease Market in the forecast period. Get your PDF Sample report with Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12115 The market is expected to be fuelled by factors such as the rising prevalence of chronic kidney disease worldwide.
— Accesswire